SG301 injection for children with frequently relapsing or steroid-dependent nephrotic syndrome
Tests SG301 injections in children with relapsing or steroid-dependent nephrotic syndrome.
Key facts
- Who runs it
- Mao Jianhua
- Where
- China1 site in 1 countryChoose a country to see its sites
- Trial code
- Registry title
- A Study of Anti-CD38 Monoclonal Antibody (SG301) Subcutaneous Injection in Children With Nephrotic Syndrome With Frequent Relapses or Steroid Dependence
- Status
- Recruiting
- Phase
- Phase 2
- People taking part
- 30 people, planned
- Started
- 25 Aug 2025
- Expected to end
- 9 Jul 2029
- Type of study
- Interventional
- Treatments tested
- SG301 Subcutaneous injection
- Record updated
- 27 February 2026
Who can take part
The trial is looking for children aged 6 to 18 with nephrotic syndrome that responds to steroids but often comes back or needs steroids to stay controlled. It tests SG301 given as an injection under the skin.
- Age
- 6 to 18 years
- Sex
- All sexes
- Disease stage
- Steroid-sensitive nephrotic syndrome with frequent relapses (FRNS) or steroid dependence (SDNS). Kidney function must be normal (eGFR ≥90 ml/min/1.73m²). After steroid treatment, urine protein must be low (morning urine protein <1+ or urine protein/creatinine <0.2 g/g (<20 mg/mmol)) for ≥3 days in a row.
- Earlier treatment
- No Tacrolimus, cyclosporine A, mycophenolate mofetil, belimumab, levamisole, azathioprine or cyclophosphamide in the past 2 months. No rituximab or obinutuzumab in the past 6 months. No earlier anti-CD38 treatment.
- Biomarker or test result
- Blood tests within 7 days before joining: hemoglobin >80 g/L, platelets >75×10⁹/L, neutrophils >1.5×10⁹/L. Prothrombin time/INR ≤1.5×ULN, unless caused by blood thinners.
- Main reasons for not taking part
- Nephrotic syndrome caused by another disease (such as IgA-related or lupus), or nephrotic syndrome that does not respond to steroids
- Family history of nephrotic syndrome, chronic glomerulonephritis or uremia
- Active hepatitis B or C, or HIV antibody-positive
- Chronic or acute active infections, other autoimmune diseases, primary immunodeficiency or cancer
- Live or weakened vaccine or major surgery within 4 weeks before the first dose
Show the full registry criteria (16)Hide the full registry criteria
Who can take part
- Aged 6 - 18 years
- Steroid-sensitive nephrotic syndrome with frequent relapses (FRNS) or steroid dependence (SDNS)
- Normal renal function: eGFR≥90 ml/min/1.73m²
- After steroid treatment, morning urine protein<1 + or urine protein/creatinine<0.2 g/g (<20 mg/mmol) for ≥3 consecutive days
- Within 7 days before enrollment, blood tests (without growth factors or transfusions) must meet: hemoglobin>80 g/L; platelets>75×10⁹/L; neutrophils>1.5×10⁹/L
- Prothrombin time/INR≤1.5×ULN, unless due to anticoagulation
- No Tacrolimus, cyclosporine A, mycophenolate mofetil, belimumab, levamisole, azathioprine, or cyclophosphamide in prior 2 months; no rituximab or obinutuzumab in prior 6 months
Who cannot take part
- Prior anti - cluster of differentiation 38 (CD38) treatment
- Live/attenuated vaccine receipt or major surgery (non - diagnostic) within 4 weeks before first dose
- Family history of nephrotic syndrome, chronic glomerulonephritis, or uremia
- HBsAg or HBcAb positive with Hepatitis B virus DNA above the lower limit of normal; Hepatitis C virus antibody - positive with Hepatitis C virus RNA positive; HIV antibody - positive
- Chronic active infections (e.g., Epstein-Barr Virus, Cytomegalovirus, tuberculosis) that may worsen with steroids/ immunosuppressants
- Acute active infection (excluding onychomycosis) requiring systemic antibiotics/antivirals
- Secondary nephrotic syndrome (e.g.,immunoglobulin A - associated, lupus nephritis); steroid - resistant nephrotic syndrome (SRNS)
- Other autoimmune diseases, primary immunodeficiency, or malignancy
- Alanine aminotransferase >2×ULN or total bilirubin>2×ULN with a sustained increase for 2 weeks
Eligibility questionnaire
From the criteria published for this trial, to help you prepare for a talk with your doctor or the study team. We do not tell you a result. Only the study team can say whether you can take part.
- Age
- Nephrotic syndrome
This trial is currently available in China.
It has sites in one country. Choose a country to see its sites.
About the trial
What the trial wants to find out
This is an open - label study to evaluate the safety, pharmacokinetics, pharmacodynamics, and preliminary efficacy of SG301 Subcutaneous injection in children with frequently relapsing or steroid - dependent nephrotic syndrome.
The group in the trial
- SG301 Subcutaneous injectionTreatment being tested
full - dose prednisone (60 mg/m²/day, up to 80 mg) for remission induction. After 3 days of negative urine protein, start SG301 Subcutaneous injection with steroid tapering. Taper prednisolone to 60 mg/m² (max 80 mg) every other day, reducing by 1/6 every 2 weeks, and stop after 3 months.
Next steps
For your doctor
Doctor ask sheet
A PDF for your doctor: what this trial tests, who can take part, and 2 eligibility questions with room for answers and notes.
PDF, US Letter, 1 to 2 pages. A4 size
For the study team
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Data and sources
- Registry record
- Listed on ClinicalTrials.gov.How to verify a trial in the registry
- Official title
- A Clinical Study to Evaluate the Initial Efficacy and Safety of Anti-CD38 Monoclonal Antibody (SG301) Subcutaneous Injection in Children With Frequent Relapses or Steroid-Dependent Nephrotic Syndrome
- Plain-language title
- SG301 injection for children with frequently relapsing or steroid-dependent nephrotic syndromeGenerated from the registry record. The registry title is the official one.
- AI summary
- From the trial's eligibility criteria. Read by machine on 15 November 2026.
- Criteria questions
- Built from NCT07087314, who can take part
- Record updated
- 27 February 2026